Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2023 Earnings Conference Call February 22, 2024 8:30 AM ET

Company Participants

Juan Sanchez - Vice President of Corporate Communications and Investor Relations

Sharon Mates - Chairman and Chief Executive Officer

Mark Neumann - Chief Commercial Officer

Suresh Durgam - Chief Medical Officer

Larry Hineline - Chief Financial Officer

Conference Call Participants

Andrew Tsai - Jefferies

Brian Abrahams - RBC Capital Markets

Na Sun - J.P. Morgan

Michael Riad - Morgan Stanley

Michael DiFiore - Evercore ISI

Marc Goodman - Leerink Partners

Joseph Thome - TD Cowen

David Amsellem - Piper Sandler

Jason Gerberry - Bank of America

Ash Verma - UBS

Sumant Kulkarni - Canaccord Genuity

Ami Fadia - Needham & Company

Charles Duncan - Cantor Fitzgerald

Operator

Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies' Fourth Quarter and Year-End Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please note that today's conference is being recorded.

I would now like to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communication and Investor Relations. Please go ahead.

Juan Sanchez

Good morning, and thank you all for joining us on our fourth quarter and full-year 2023 earnings call. Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Chief Commercial Officer; Dr. Suresh Durgam, Chief Medical Officer; and Larry Hineline, Chief Financial Officer.

As a reminder, during today's call, we will be making certain forward-looking statements. These forward-looking statements are based on current information, assumptions, and expectations. These are subject to change and involve a number of risks and uncertainties that might cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements, and the company disclaims any obligations to update such statements.

Sharon?

Sharon Mates

Thanks, Juan. Good morning, everyone, and welcome to today's call. We're excited to share our results for the fourth quarter and the full-year 2023. This past year was defined by strong and consistent growth throughout our company. We achieved major milestones as we established CAPLYTA as a key treatment option for broad patient populations with bipolar depression and schizophrenia. We also advanced our pipeline programs, and look forward to announcing top line results in our major depressive disorder study, Study 501 and Study 502.